IJR News — today's news from every side
open
serve
block
verse
w
o
rdys
billionaire
.ai
your
list
Whiteboard
App
quizie
un
school
New Journal
News
Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News
Ask Genius
Apps
Ask Genius
Apps
Trending
Cellectis Exits Two CAR-T Programs, Advances Gene Editing
x/cellectis
— 5h
Cellectis announced a strategic transformation to become an in vivo gene editing company, shifting resources to two lead programs HEAL-101 and HEAL-201 for severe dyslipidemias and exiting lasme-cel and eti-cel to extend its cash runway into the second half of 2028, while realigning its operating model around the in vivo pipeline. Phase 1 data are planned for HEAL-101 in the second half of 2027 and for HEAL-201 in the first half of 2028, with ongoing cell therapy partnerships and a September 14 conference call to discuss updates.
+2
2
Share
Dana Whitfield
Exiting the CAR-T candidates to reach 2028 cash runway is understandable but leaves them with pretty distant phase 1 readouts.
